• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Rigel Pharmaceuticals Inc

+ Add to Watchlist


2.2300 USD 0.0800 3.46%

As of 20:10:00 ET on 09/12/2014.

Snapshot for Rigel Pharmaceuticals Inc (RIGL)

Open: 2.3200 Day's Range: 2.2000 - 2.3300 Volume: 643,595
Previous Close: 2.3100 52wk Range: 2.1200 - 5.0000 1-Yr Rtn: -39.05%

Stock Chart for RIGL

No chart data available.
  • RIGL:US 2.2300
  • 1D
  • 1M
  • 1Y
Interactive RIGL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RIGL

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.9900
Est. EPS (USD) (12/2014) -1.0840
Est. PEG Ratio -
Market Cap (M USD) 195.78
Shares Outstanding (M) 87.79
30 Day Average Volume 488,374
Price/Book (mrq) 1.1813
Price/Sale (ttm) 33.9076
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/05/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RIGL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RIGL

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The Company's research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.

James M GowerChairman/CEORaul R RodriguezPresident/COO
Ryan D MaynardExec VP/CFOElliott B GrossbardExec VP/Chief Medical Officer
More Company Profile & Key Executives for RIGL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil